The Asia Pacific antifungal agents market is estimated to grow with a CAGR of around 5.39% over the forecast period of 2018-2026. Increased awareness about the therapeutic potential of antifungal agents is expected to propel the growth of the market in this region. The countries analyzed in the Asia Pacific antifungal drugs market are India, China, Japan, Japan, South Korea, Taiwan and rest of APAC. In the global antifungal drugs market, Asia Pacific is expected to be the fastest evolving region.

ASIA-PACIFIC ANTIFUNGAL AGENTS MARKET FORECAST 2018-2026

Asia pacific Antifungal Agents Market by Drug Types (Echinocandins, Azoles, Polyenes, Allylamines & Others) by Therapeutic Indications (Aspergillosis, Dermatophytosis, Candidiasis, Others) by Applications (Topical Antifungal Drugs, Oral Drugs) by Geography

Request free sample

Report Summary

The countries analyzed in the Asia Pacific antifungal drugs market are India, China, Japan, Japan, South Korea, Taiwan and rest of APAC. In the global antifungal drugs market, Asia Pacific is expected to be the fastest evolving region. However, strict rules and regulation and difficulty in approvals are the factors declining the growth of the antifungal drugs market in the Asia Pacific region. For instance, the Pharmaceutical Affairs Law of Japan requires a license for marketing authorization when importing and selling pharmaceutical products manufactured in other countries. The license may be revoked if the quality management methods and postmarketing safety management methods applied with respect to the pharmaceutical product fail to conform to the standards stipulated in the ordinances promulgated by the Ministry of Health, Labour and Welfare.

The key companies of the antifungal drugs market mentioned in the report are Vertex Pharmaceuticals, Abbott Laboratories, Bayer Healthcare, Baxter, Johnson & Johnson, Astellas Pharma Inc, Novartis, GlaxoSmithKline, Arbor Pharmaceuticals Inc, Pfizer, Kramer Laboratories, Sanofi-Aventis, Teva Pharmaceuticals, and Gilead.

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

RESEARCH SCOPE
- STUDY GOALS
- SCOPE OF THE MARKET STUDY
- WHO WILL FIND THIS REPORT USEFUL?
- STUDY AND FORECASTING YEARS
RESEARCH METHODOLOGY
- SOURCES OF DATA
  - SECONDARY DATA
  - PRIMARY DATA
- TOP DOWN APPROACH
- BOTTOM-UP APPROACH
- DATA TRIANGULATION
- ESTIMATION METHODOLOGY
EXECUTIVE SUMMARY
- MARKET SUMMARY
- KEY FINDINGS
  - TROPICAL DRUGS MARKET IS THE EMERGING APPLICATION
  - ASPERGILLOSIS THERAPEUTIC INDICATION IS LEADING THE MARKET

MARKET DETERMINANTS
- MARKET DRIVERS
  - POOR HYGIENE HABITS
  - DEVELOPMENT OF DRUG RESISTANCE
  - HEALTHCARE POLICIES AND PROGRAMS BY GOVERNMENT
- MARKET RESTRAINTS
  - ALTERNATE TREATMENT OPTIONS
  - REGULATORY ATMOSPHERE
- MARKET OPPORTUNITIES
  - EMERGING PIPELINE OF NEW AND INNOVATIVE ANTIFUNGAL DRUGS
  - HEALTHCARE AND RELATED INDUSTRIES ARE GROWING CONTINUOUSLY
  - INCREASING AWARENESS AND AVAILABILITY OF INFORMATION
- MARKET CHALLENGES
  - GROWTH AND DEVELOPMENT OF THE GENERIC ANTIFUNGAL DRUGS MARKET
  - SIDE EFFECTS AND RECURRING FUNGAL INFECTIONS
  - RESISTANCE TO DRUGS
  - RAPIDLY CHANGING TECHNOLOGY

MARKET SEGMENTATION
- MARKET BY DRUG TYPES 2018-2026
  - SYSTEMIC AZOLES
  - TOPICAL AZOLES
  - SYSTEMIC POLYENES
  - TOPICAL POLYENES
  - SYSTEMIC ECHINOCANDINS
  - SYSTEMIC ANTIMETABOLICS
  - OTHER SYSTEMIC
  - OTHER TOPICAL
  - OTHER DRUGS TYPES
- MARKET BY THERAPEUTIC INDICATIONS 2018-2026
  - ASPERGILLOSIS MARKET
  - DERMATOPHYTOSIS MARKET
  - CANDIDIASIS MARKET
  - OTHER THERAPEUTIC INDICATION MARKET
- MARKET BY APPLICATIONS 2018-2026
  - TOPICAL ANTIFUNGAL AGENTS MARKET
  - ORAL DRUGS MARKET
- MARKET BY TYPES 2018-2026
  - PRESCRIPTION
  - OVER THE COUNTER (OTC)

KEY ANALYTICS
- PORTER’S FIVE FORCE MODEL
  - THREAT OF NEW ENTRANTS
  - THREAT OF SUBSTITUTE PRODUCTS OR SERVICES
  - BARGAINING POWER OF BUYER
  - BARGAINING POWER OF SUPPLIER
  - INTENSITY OF COMPETITIVE RIVALRY
- KEY BUYING CRITERIA
- VALUE CHAIN ANALYSIS
  - MANUFACTURERS
  - DISTRIBUTORS
  - RETAILERS
  - END-USERS
- REGULATORY FRAMEWORK
  - REGULATION IN ASIA PACIFIC
- OPPORTUNITY MATRIX
GEOGRAPHICAL ANALYSIS
- ASIA PACIFIC
  - INDIA
  - CHINA
  - JAPAN
  - SOUTH KOREA
  - TAIWAN
  - REST OF APAC

COMPANY PROFILES
- COMPETITIVE LANDSCAPE
  - MARKET SHARE ANALYSIS
- ABBOTT LABORATORIES.
  - COMPANY OVERVIEW
  - PRODUCT PORTFOLIO
  - SCOT ANALYSIS
  - STRATEGIC INITIATIVES
- ARBOR PHARMACEUTICALS, INC.
  - COMPANY OVERVIEW
  - PRODUCT PORTFOLIO
  - SCOT ANALYSIS
  - STRATEGIC INITIATIVES
- BAXTER
  - COMPANY OVERVIEW
  - PRODUCT PORTFOLIO
  - SCOT ANALYSIS
  - STRATEGIC INITIATIVES
- ASTELLAS PHARMA INC.
  - COMPANY OVERVIEW
  - PRODUCT PORTFOLIO
  - SCOT ANALYSIS
  - STRATEGIC INITIATIVES
- BAYER HEALTHCARE
  - COMPANY OVERVIEW
  - PRODUCT PORTFOLIO
  - SCOT ANALYSIS
  - STRATEGIC INITIATIVE
- TEVA PHARMACEUTICALS
  - COMPANY OVERVIEW
  - PRODUCT PORTFOLIO
  - SCOT ANALYSIS
  - STRATEGIC INITIATIVES
- GILEAD
  - COMPANY OVERVIEW
  - PRODUCT PORTFOLIO
  - SCOT ANALYSIS
  - STRATEGIC INITIATIVES
- GLAXOSMITHKLINE
  - COMPANY OVERVIEW
  - PRODUCT PORTFOLIO
  - SCOT ANALYSIS
  - STRATEGIC INITIATIVES
- JOHNSON & JOHNSON
  - COMPANY OVERVIEW
  - PRODUCT PORTFOLIO
  - SCOT ANALYSIS
  - STRATEGIC INITIATIVES
- KRAMER LABORATORIES
  - COMPANY OVERVIEW
  - PRODUCT PORTFOLIO
  - SCOT ANALYSIS
- MERCK & CO.
  - COMPANY OVERVIEW
  - PRODUCT PORTFOLIO
  - SCOT ANALYSIS
  - STRATEGIC INITIATIVES
- NOVARTIS
  - COMPANY OVERVIEW
  - PRODUCT PORTFOLIO
  - SCOT ANALYSIS
  - STRATEGIC INITIATIVES
- PFIZER
  - COMPANY OVERVIEW
  - PRODUCT PORTFOLIO
  - SCOT ANALYSIS
  - STRATEGIC INITIATIVES
- SANOFI-AVENTIS
  - COMPANY OVERVIEW
  - PRODUCT PORTFOLIO
  - SCOT ANALYSIS
  - STRATEGIC INITIATIVE
- VERTEX PHARMACEUTICALS
  - COMPANY OVERVIEW
  - PRODUCT PORTFOLIO
  - SCOT ANALYSIS
  - STRATEGIC INITIATIVE

TABLE LIST

TABLE 1 ASIA PACIFIC ANTIFUNGAL AGENTS MARKET 2018-2026 ($MILLION)

TABLE 2 SKIN LESIONS OCCURRING DUE TO ANTIFUNGAL INFECTION

TABLE 3 INDIAN GOVERNMENT INITIATIVES IN HEALTHCARE SECTOR

TABLE 4 ASIA PACIFIC ANTIFUNGAL AGENTS MARKET BY DRUG TYPES MARKET 2018-2026 ($ MILLION)

TABLE 5 DRUG USES OF TRIAZOLES

TABLE 6 ASIA PACIFIC ANTIFUNGAL AGENTS MARKET IN SYSTEMIC AZOLES 2018-2026 ($ MILLION)

TABLE 7 ASIA PACIFIC ANTIFUNGAL AGENTS MARKET IN TOPICAL AZOLES 2018-2026 ($ MILLION)

TABLE 8 ASIA PACIFIC ANTIFUNGAL AGENTS MARKET IN SYSTEMIC POLYENES 2018-2026 ($ MILLION)

TABLE 9 ASIA PACIFIC ANTIFUNGAL AGENTS MARKET IN TOPICAL POLYENES 2018-2026 ($ MILLION)

TABLE 10 INDICATION AND DOSES OF ECHINOCANDIN BY US APPROVED DRUG USAGE

TABLE 11 ASIA PACIFIC ANTIFUNGAL AGENTS MARKET IN SYSTEMIC ECHINOCANDINS 2018-2026 ($ MILLION)

TABLE 12 ASIA PACIFIC ANTIFUNGAL AGENTS MARKET IN SYSTEMIC ANTIMETABOLICS 2018-2026 ($ MILLION)

TABLE 13 ASIA PACIFIC ANTIFUNGAL AGENTS MARKET IN OTHER SYSTEMIC 2018-2026 ($ MILLION)

TABLE 14 ASIA PACIFIC ANTIFUNGAL AGENTS MARKET IN OTHER TOPICAL 2018-2026 ($ MILLION)

TABLE 15 ASIA PACIFIC ANTIFUNGAL AGENTS MARKET IN OTHER DRUGS TYPES MARKET 2018-2026 ($ MILLION)

TABLE 16 ASIA PACIFIC ANTIFUNGAL AGENTS MARKET BY THERAPEUTIC INDICATIONS MARKET 2018-2026 ($ MILLION)

TABLE 17 ASIA PACIFIC ANTIFUNGAL AGENTS MARKET IN ASPERGILLOSIS 2018-2026 ($ MILLION)

TABLE 18 SYMPTOMS IN THE AFFECTED AREA CAUSED BY DERMATOPHYTES

TABLE 19 ASIA PACIFIC ANTIFUNGAL AGENTS MARKET IN DERMATOPHYTOSIS MARKET 2018-2026 ($ MILLION)

TABLE 20 SYMPTOMS IN THE AFFECTED AREA CAUSED BY CANDIDIASIS

TABLE 21 ASIA PACIFIC ANTIFUNGAL AGENTS MARKET IN CANDIDIASIS 2018-2026 ($ MILLION)

TABLE 22 ASIA PACIFIC ANTIFUNGAL AGENTS MARKET IN OTHER THERAPEUTIC INDICATION 2018-2026 ($ MILLION)

TABLE 23 ASIA PACIFIC ANTIFUNGAL AGENTS MARKET BY APPLICATIONS MARKET 2018-2026 ($ MILLION)

TABLE 24 PROS AND CONS OF TOPICAL MEDICATIONS

TABLE 25 ANTIFUNGAL POWDERS AND IT’S EFFECT

TABLE 26 ANTIFUNGAL OINTMENT AND IT’S EFFECT

TABLE 27 ANTIFUNGAL PASTES AND IT’S EFFECT

TABLE 28 ASIA PACIFIC ANTIFUNGAL AGENTS MARKET IN TOPICAL ANTIFUNGAL AGENTS 2018-2026 ($ MILLION)

TABLE 29 COMMONLY USED ANTIFUNGAL DRUGS DOSAGE AND IT’S EFFECTS

TABLE 30 ASIA PACIFIC ANTIFUNGAL AGENTS MARKET IN ORAL DRUGS 2018-2026 ($ MILLION)

TABLE 31 ASIA PACIFIC ANTIFUNGAL AGENTS MARKET BY TYPES 2018-2026 ($ MILLION)

TABLE 32 ASIA PACIFIC ANTIFUNGAL AGENTS MARKET IN PRESCRIPTION 2018-2026 ($ MILLION)

TABLE 33 ASIA PACIFIC ANTIFUNGAL AGENTS MARKET IN OTC 2018-2026 ($ MILLION)

TABLE 34 ASIA PACIFIC ANTIFUNGAL AGENTS MARKET BY COUNTRIES 2018-2026($ MILLION)

TABLE 35 INDIA’S HEALTHCARE SECTOR INVESTMENT

TABLE 36 COMPANIES IN CHINA PRODUCING ANTIFUNGAL DRUGS

FIGURES LIST

FIGURE 1 ASIA PACIFIC ANTIFUNGAL AGENTS MARKET 2018-2026 ($MILLION)

FIGURE 2 TOPICAL ANTIFUNGAL AGENTS TYPES

FIGURE 3 PORTER’S FIVE FORCE MODEL IN ANTIFUNGAL AGENTS MARKET

FIGURE 4 VALUE CHAIN OF ANTIDEPRESSANT DRUGS

FIGURE 5 INDIA ANTIFUNGAL AGENTS MARKET 2018-2026($ MILLION)

FIGURE 6 CHINA ANTIFUNGAL AGENTS MARKET 2018-2026($ MILLION)

FIGURE 7 JAPAN ANTIFUNGAL AGENTS MARKET 2018-2026($ MILLION)

FIGURE 8 SOUTH KOREA ANTIFUNGAL AGENTS MARKET 2018-2026($ MILLION)

FIGURE 9 TAIWAN ANTIFUNGAL AGENTS MARKET 2018-2026($ MILLION)

FIGURE 10 REST OF APAC ANTIFUNGAL AGENTS MARKET 2018-2026($ MILLION)

FIGURE 11 ANTI-FUNGAL AGENT COMPANY MARKET SHARE ANALYSIS 2017 (%)

Segmentation

GEOGRAPHICAL ANALYSIS
- ASIA PACIFIC
  - INDIA
  - CHINA
  - JAPAN
  - SOUTH KOREA
  - TAIWAN
  - REST OF APAC

MARKET SEGMENTATION
- MARKET BY DRUG TYPES 2018-2026
  - SYSTEMIC AZOLES
  - TOPICAL AZOLES
  - SYSTEMIC POLYENES
  - TOPICAL POLYENES
  - SYSTEMIC ECHINOCANDINS
  - SYSTEMIC ANTIMETABOLICS
  - OTHER SYSTEMIC
  - OTHER TOPICAL
  - OTHER DRUGS TYPES
- MARKET BY THERAPEUTIC INDICATIONS 2018-2026
  - ASPERGILLOSIS MARKET
  - DERMATOPHYTOSIS MARKET
  - CANDIDIASIS MARKET
  - OTHER THERAPEUTIC INDICATION MARKET
- MARKET BY APPLICATIONS 2018-2026
  - TOPICAL ANTIFUNGAL AGENTS MARKET
  - ORAL DRUGS MARKET
- MARKET BY TYPES 2018-2026
  - PRESCRIPTION
  - OVER THE COUNTER (OTC)